血府逐瘀口服液联合生长抑素治疗急性胰腺炎的临床研究

目的探讨血府逐瘀口服液联合生长抑素治疗急性胰腺炎的临床疗效。方法选取2012年10月-2014年4月内蒙古医科大学附属医院收治的急性胰腺炎患者98例，随机分成治疗组（49例）和对照组（49例），对照组在常规治疗的基础上给予注射用生长抑素0．25mg／h，经微泵持续静脉泵注；治疗组在对照组治疗的基础上121服血府逐瘀口服液，10mL／次，3次／d。两组均连续治疗7d。观察两组患者的临床疗效，同时比较两组腹痛缓解时间、胃肠功能恢复时间、血尿淀粉酶正常时间、白细胞计数恢复时间、并发症发生率等临床指标以及血清肿瘤坏死因子-α（TNF-α）、白细胞介素-1β（IL-1β）、血浆内皮素（ET）、血栓素B2（TXB2）及-6酮前列腺素-F1α（6-keto-Flα）的水平变化。结果治疗组和对照组的总有效率分别为95.92％、85．71％，两组比较差异有统计学意义（P〈0．05）。治疗组患者在腹痛缓解时间、胃肠功能恢复时间、血尿淀粉酶恢复时间、白细胞计数恢复时间、并发症发生率方面均显著低于对照组，两组比较差异具有统计学意义（P〈0．05）。治疗后，两组患者的TNF-α、IL-1β、ET、TXB2、6-keto-PGFlα均较治疗前有显著降低，同组治疗前后差异有统计学意义（P〈0．05、0．01）。治疗后，治疗组这些指标明显低于对照组，两组比较差异有统计学意义（P〈O．05、0．01）。结论血府逐瘀口服液联合生长抑素对急性胰腺炎有较好的临床疗效，可能与减轻患者的炎症反应，改善微循环有关。

Clinical research of Xuefu Zhuyu Oral Liquid combined with somatostatin in treatment of acute pancreatitis

Objective To investigate the therapeutic efficacy of Xuefu Zhuyu Oral Liquid combined with somatostatin in the treatment of acute pancreatitis. Methods Patients （98 cases） suffered from acute pancreatitis in Affiliated Hospital of Inner Mongolia Medical University from October 2012 to April 2014 were randomly divided into treatment （49 cases） and control （49 cases） groups. The patients in the control group were given somatostatin 0.25 mg/h through micro-vein continuous iv pumping on the basis of conventional treatment. The patients in the treatment group were po administered with Xuefu Zhuyu Oral Liquid, 10 mL/time, three times daily. All the patients were treated continuously for 7 d. The total clinical efficacy was observed, and clinical indicators such as abdominal pain relief time, gastrointestinal fimction recovery time, blood and urine amylase turn normal time, white blood cell count recovery time, and incidence of complications were compared. At the same time, the levels of tumor necrosis factor-α （TNF-α）, interleukin-1 （IL-1β）, endothelin （ET）, thromboxane B2 （TXB2）, and 6-keto-prostaglandin-Flα（6-keto-Flα） were compared. Results The total effective rates of the treatment and control groups were 95.92% and 85.71%, respectively, with the significant difference between the two groups （P 〈 0.05）. Abdominal pain relief time, gastrointestinal function recovery time, blood and urine amylase turn normal time, white blood cell count recovery time, and incidence of complications in the treatment group were significantly lower than those in the control group, with the significant difference between the two groups （P 〈 0.05）. After the treatment, the levels of TNF-α, IL-1β, ET, TXB2, and 6-keto-PGFlα in the two groups were significantly lower than before the treatment, with statistically significant difference before and after treatment in the same group （P 〈 0.05, 0.01）. After the treatment, those indexes in the treatment group were significantly lower than